Eugene Lin, MD, MS, FASN

Associate Professor of Medicine and Health Policy and Management

Image of Eugene Lin, MD, MS, FASN
Is this your profile? Click to edit

Overview

Eugene Lin, MD, MS, is a nephrologist and health services researcher with a focus on economic policies pertaining to kidney disease. He is a nationally recognized expert on the impact of public policy and federal regulation on kidney care, the provision of dialysis in public and private insurance markets, and transitions of care for patients with kidney disease. He is an NIH funded investigator, and his work has been published in leading health policy and medical journals, including JAMA, Health Affairs, and JAMA Internal Medicine.

In addition to his academic roles at USC, he currently serves on the National Kidney Foundation’s Scientific Advisory Board and the American Society of Nephrology’s Transplant Policy Committee. He has also participated as a key stakeholder in multiple Technical Expert Panels for the Centers for Medicare and Medicaid Services.

Dr. Lin completed a postdoctoral fellowship in nephrology at the Stanford School of Medicine and completed his Internal Medicine residency at the Hospital of the University of Pennsylvania.

Education and Training

  • USC, Los Angeles, CA — Visiting Scholar — 2018
  • Stanford University School of Medicine, Palo Alto, CA — Fellow — 2018 — Nephrology
  • Stanford University, Stanford, CA — M.S. — 2017 — Health Services Research
  • Hospital of the University of Pennsylvania, Philadelphia, CA — Resident — 2014 — Internal Medicine
  • Hospital of the University of Pennsylvania, Philadelphia, CA — Intern — 2012
  • Baylor College of Medicine, Houston, TX — M.D. — 2011 — Medicine
  • Stanford University, Stanford, CA — B.S. — 2006 — Biology, minor in Mathematics

Research Funding

  • Elucidating the Mechanisms of Racial and Ethnic Disparities in Dialysis Quality
    NIH · R01DK137223 · Sep 1, 2023 – Jun 30, 2028 · Role: Principal Investigator
  • Comparing Dialysis Provision and Outcomes Between Medicare Advantage and Fee-for-Service Medicare
    NIH · R03DK131239 · Jul 1, 2022 – Jun 30, 2024 · Role: Principal Investigator
  • The Impact of Medicare Advantage on Patients with End-Stage Kidney Disease
    American Society of Nephrology (KidneyCure) · Jul 1, 2021 – Jun 30, 2023 · Role: Principal Investigator
  • Investigating the Economic and SocialDeterminants of Home Dialysis Drop-Out
    NIH · K08DK118213 · Aug 15, 2018 – May 31, 2024 · Role: Principal Investigator
  • Investigating the Appropriateness of 30-Day Rehospitalizations in Dialysis Patients
    NIH · F32DK107123 · Jul 20, 2015 – Jul 19, 2018 · Role: Principal Investigator

Research Keywords

  • Dialysis Delivery
  • Multidisciplinary Care in Kidney Disease
  • Value-Based Purchasing
  • Medicare Payment Policy
  • Decision Analysis

Publications

  • Seasonality, Hospitalization, and Initiation of Home Dialysis: A Retrospective Cohort Study. Am J Kidney Dis. 2026 Aug; 88(2):226-237.e1.. View in PubMed
  • How Do We Boost Home Dialysis? JAMA Netw Open. 2026 Apr 01; 9(4):e266125. Lin E , Cervantes L . View in PubMed
  • Implications of Acute Kidney Injury Requiring Dialysis Versus End-Stage Kidney Disease Status. Am J Kidney Dis. 2026 Jun; 87(6):867-874.. View in PubMed
  • From Legislation to Kidney Care: Unpacking the Impact of the New Budget Reconciliation Act. J Am Soc Nephrol. 2026 Jun 01; 37(6):1332-1334.. View in PubMed
  • What is Medicare Advantage and Why is it the Most Important Contemporary Policy Affecting Kidney Disease? Am J Kidney Dis. 2026 Feb; 87(2):260-269. Caldwell JS, Lin E . . View in PubMed
  • Center behavior and location, and its impact on transplant disparities. Am J Transplant. 2025 Nov; 25(11):2290-2291.. View in PubMed
  • Preoperative Dialysis Dose and Postoperative Outcomes in Patients Receiving Maintenance Hemodialysis. Kidney360. 2025 Nov 01; 6(11):1948-1959.. View in PubMed
  • Hemodiafiltration Should Be the Primary In-Center Kidney Replacement Modality in ESKD: CON. Kidney360. 2025 Oct 01; 6(10):1652-1654.. View in PubMed
  • Is Medicare Advantage Advertising Helping or Hurting Patients Receiving Dialysis? JAMA Netw Open. 2025 Jun 02; 8(6):e2516364. Lin E . View in PubMed
  • Calcimimetic Prescriptions in Fee-for-Service Medicare Beneficiaries Undergoing Dialysis. JAMA Health Forum. 2025 Apr 04; 6(4):e250452.. View in PubMed